Medigene AG extends protection of its KRAS library with filing of new patent application in support of MDG2021

Planegg/Martinsried (pta007/25.09.2024/09:00 UTC+2)

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the discovery and development of T-cell receptor (TCR)-driven therapies for the treatment of cancer, today announced the filing of a new patent application with the European Patent Office protecting MDG2021, a T-cell receptor-engineered T-cell (TCR-T) therapy targeting Kirsten rat sarcoma viral oncogene homologue (KRAS) G12D with human leukocyte antigen (HLA)-A*11, for TCR-T therapy alone and in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology. MDG2021 is the second candidate within the KRAS library targeting KRAS G12D (HLA-A*11) for which the Company announced lead selection in June 2024. The addition of MDG2021 to the company’s KRAS-targeted TCR library has a significant impact on the patient population to be addressed with the combination of KRAS G12V and KRAS G12D mutations accounting for ~50% of all KRAS mutations in all tumors (pan cancer), or even >70% in pancreatic adenocarcinoma. (Yang et al., J Clin Med 2023)

“We are pleased to announce the patent application for MDG2021, our optimal affinity 3S (sensitive, specific and safe) TCR targeting KRAS G12D (HLA-A*11), alone and in combination with our PD1-41BB armoring and enhancement CSP,” said Selwyn Ho CEO of Medigene. “This application validates our commitment to expanding our intellectual property for TCRs targeting both neoantigens and cancer testis antigens that have potential utility in multiple TCR-driven treatment modalities, including TCR-T therapies such as MDG2021, as well as TCR-driven T cell engager therapies (MDG3010) and TCR-natural killer cell therapies.”

Medigene is continually expanding and strengthening its patent portfolio with new technologies and extending existing patents to additional jurisdictions. The company maintains 29 different patent families worldwide covering applications protecting Medigene’s 3S TCRs and its exclusive E2E Platform technologies.

— end of press release —

About Medigene AG

Medigene AG (FSE: MDG1) is an immuno-oncology platform company focused on the development of T cell receptor (TCR)-guided therapies to effectively eliminate cancer. The End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinguishing characteristics that are used in multiple therapeutic modalities such as T cell receptor-engineered T cell (TCR-T) therapies, TCR-guided T cell engager therapies and TCR natural killer cell therapies for both its internal product pipeline and partnerships.

Medigene’s lead TCR-T program, MDG1015, is a potential best-in-class TCR-T therapy for the treatment of multiple solid tumor indications. The End-to-End Platform technologies enable the armoring and enhancement of these T cells to overcome the immunosuppressive tumor microenvironment (TME) and ensure that the composition of the T cell drug product maximizes the safety, efficacy and durability of the response. Medigene’s MDG1015 received IND approval in Q3 2024 and is filing a CTA in Q4 2024. For more information, visit https://medigene.com/

About Medigene’s End-to-End Platform

Medigene’s approach to immunotherapy harnesses the immense power of natural T-cell receptors. By combining these TCRs with various components of the immune system, such as T-cells, natural killer (NK) cells or a CD3 complex (TCE, T-cell engager), highly specific, sensitive and safe modalities are formed to complement and/or activate the body’s defense systems against cancer. Medigene’s comprehensive End-to-End (E2E) platform is built on a foundation of proprietary and advanced technologies, driving the development of highly specific TCR-guided therapies, including the latest advances in TCR-T, TCR-NK and TCR-TCE therapeutics. The E2E platform includes advanced TCR generation and optimization techniques, such as Allogeneic-HLA TCR Priming, and integrates advanced product armoring and enhancement features such as PD1-41BB and CD40L-CD28 Costimulatory Switch Proteins and iM-TCR. In addition, the E2E platform offers solutions for the development of optimal cell therapy medicines for improved safety, efficacy and sustainability. Collaborations with partners such as BioNTech, Regeneron and WuXi Biologics underscore the capabilities of the platform and its potential to revolutionize cancer treatment.

This press release contains forward-looking statements that represent the views of Medigene as of the date of this press release. Actual results achieved by Medigene may differ materially from the forward-looking statements made herein. Medigene assumes no obligation to update these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed only in certain locations.

Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
Email address: [email protected]

If you no longer wish to receive information about Medigene, you can let us know by email ([email protected]). We will then remove your address from our distribution list.

(end)